ATE442386T1 - Immunoadhesin zur impfung gegen rhinovirus - Google Patents

Immunoadhesin zur impfung gegen rhinovirus

Info

Publication number
ATE442386T1
ATE442386T1 AT01930958T AT01930958T ATE442386T1 AT E442386 T1 ATE442386 T1 AT E442386T1 AT 01930958 T AT01930958 T AT 01930958T AT 01930958 T AT01930958 T AT 01930958T AT E442386 T1 ATE442386 T1 AT E442386T1
Authority
AT
Austria
Prior art keywords
immunoadhesions
present
immunoadhesin
useful
contain
Prior art date
Application number
AT01930958T
Other languages
English (en)
Inventor
James Larrick
Keith Wycoff
Original Assignee
Planet Biotechnology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Planet Biotechnology Inc filed Critical Planet Biotechnology Inc
Application granted granted Critical
Publication of ATE442386T1 publication Critical patent/ATE442386T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70525—ICAM molecules, e.g. CD50, CD54, CD102
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
    • C12N15/8257—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
    • C12N15/8257—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon
    • C12N15/8258—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon for the production of oral vaccines (antigens) or immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32711—Rhinovirus
    • C12N2770/32722—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT01930958T 2000-04-28 2001-04-28 Immunoadhesin zur impfung gegen rhinovirus ATE442386T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20029800P 2000-04-28 2000-04-28
PCT/US2001/013932 WO2001083529A2 (en) 2000-04-28 2001-04-28 Immunoadhesin for the prevention of rhinovirus infection

Publications (1)

Publication Number Publication Date
ATE442386T1 true ATE442386T1 (de) 2009-09-15

Family

ID=22741119

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01930958T ATE442386T1 (de) 2000-04-28 2001-04-28 Immunoadhesin zur impfung gegen rhinovirus

Country Status (11)

Country Link
US (1) US7951378B2 (de)
EP (1) EP1290027B1 (de)
JP (1) JP5008811B2 (de)
CN (2) CN101643512A (de)
AT (1) ATE442386T1 (de)
AU (2) AU2001257445B2 (de)
CA (1) CA2407426A1 (de)
DE (1) DE60139864D1 (de)
DK (1) DK1290027T3 (de)
ES (1) ES2332872T3 (de)
WO (1) WO2001083529A2 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030035798A1 (en) 2000-08-16 2003-02-20 Fang Fang Humanized antibodies
US20020168367A1 (en) * 2000-04-28 2002-11-14 Planet Biotechnology Incorporated Novel immunoadhesins for treating and preventing viral and bacterial diseases
ATE442386T1 (de) 2000-04-28 2009-09-15 Planet Biotechnology Inc Immunoadhesin zur impfung gegen rhinovirus
WO2003062370A2 (en) 2001-07-19 2003-07-31 Perlan Therapeutics, Inc. Multimeric proteins and methods of making and using same
CA2617877A1 (en) * 2005-08-02 2007-04-19 Planet Biotechnology, Inc. Improved chimeric toxin receptor proteins and chimeric toxin receptor proteins for treatment and prevention of anthrax
WO2013049254A1 (en) * 2011-09-26 2013-04-04 Jn Biosciences Llc Hybrid constant regions
US9382319B2 (en) 2011-09-26 2016-07-05 Jn Biosciences Llc Hybrid constant regions
DK3105250T3 (da) * 2014-02-10 2020-09-28 Igm Biosciences Inc Multispecifikke iga-bindingsmolekyler
IL292311A (en) 2014-04-03 2022-06-01 Igm Biosciences Inc J-chain qualified
SG11201707144VA (en) 2015-03-04 2017-09-28 Igm Biosciences Inc Cd20 binding molecules and uses thereof
US11639389B2 (en) 2015-09-30 2023-05-02 Igm Biosciences, Inc. Binding molecules with modified J-chain
CA2999284C (en) 2015-09-30 2023-06-13 Igm Biosciences A/S Binding molecules with modified j-chain
WO2021183404A1 (en) 2020-03-07 2021-09-16 Planet Biotechnology, Inc. Ace2-fc fusion proteins for sars-cov-2 mitigation
CN114767834A (zh) * 2022-05-11 2022-07-22 杭州医学院 Icam-1多肽或基因在制备治疗修复睾丸中生精障碍的药物中的应用
CN116059169B (zh) * 2023-02-07 2025-03-11 余姚市人民医院 一种血管内皮细胞靶向载药胶束及其制备方法和应用
KR102912267B1 (ko) 2023-04-20 2026-01-15 한국화학연구원 신규한 헤테로고리 화합물 또는 이의 약학적으로 허용가능한 염 및 이를 유효성분으로 포함하는 바이러스성 질환의 예방 또는 치료용 약학적 조성물
CN117538545B (zh) 2024-01-09 2024-07-05 上海众启生物科技有限公司 一种用于阿尔茨海默症检测的蛋白抗原组合及应用
CN121574206B (zh) * 2026-01-28 2026-04-07 中国科学院烟台海岸带研究所 一种具有ace抑制活性的五肽es5及其制备方法和应用

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4873191A (en) * 1981-06-12 1989-10-10 Ohio University Genetic transformation of zygotes
US4443549A (en) * 1981-10-19 1984-04-17 Molecular Genetics, Inc. Production of monoclonal antibodies against bacterial adhesins
US4652448A (en) * 1982-10-07 1987-03-24 Molecular Genetics, Inc. Use of monoclonal antibodies against bacterial adhesins
US4870009A (en) * 1982-11-22 1989-09-26 The Salk Institute For Biological Studies Method of obtaining gene product through the generation of transgenic animals
US5034322A (en) * 1983-01-17 1991-07-23 Monsanto Company Chimeric genes suitable for expression in plant cells
US5352605A (en) * 1983-01-17 1994-10-04 Monsanto Company Chimeric genes for transforming plant cells using viral promoters
GB8303994D0 (en) * 1983-02-14 1983-03-16 Council Of Governors Of United Antigenic materials
FI68590C (fi) * 1984-03-15 1985-10-10 Rosenlew Ab Oy W Flexibel behaollare foer transport och lagring av massagods
US4736866B1 (en) * 1984-06-22 1988-04-12 Transgenic non-human mammals
AU6137986A (en) 1985-07-16 1987-02-10 Salk Institute For Biological Studies, The Genetic alteration of plants with retroviruses
NZ217113A (en) * 1985-08-07 1988-06-30 Monsanto Co Production of eucaryotic plants which are glyphosate resistant, vectors (transformation and expression), chimeric gene and plant cells
US5352446A (en) * 1986-03-25 1994-10-04 Council Of Governors Of The United Medical And Dental Schools Of Guy's And St. Thomas's Hospitals Method of treating dental caries with monoclonal antibodies against the antigen I and antigen I/II of streptococcus mutans
US5518721A (en) * 1987-02-27 1996-05-21 Council Of Governors Of The United Medical And Dental Schools Of Guy's And St. Thomas Hospital Antibodies against Streptococcus
GB8704648D0 (en) 1987-02-27 1987-04-01 Guy S & St Thomas S Hospitals Antibodies
US5258498A (en) * 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US5352440A (en) * 1988-03-30 1994-10-04 Trustees Of Boston University Methods for increasing melanin content in melanocytes using diacylglycerols and uses thereof
ATE126005T1 (de) * 1988-04-25 1995-08-15 Monsanto Co Insektenresistente salatpflanzen.
US5183756A (en) * 1988-08-19 1993-02-02 The United States Of America As Represented By The Department Of Health And Human Services Monoclonal antibody (D612) having selective reactivity for gastrointestinal caricinomas and method for employing the same
US5116964A (en) * 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
CA2016842A1 (en) 1989-05-16 1990-11-16 Richard A. Lerner Method for tapping the immunological repertoire
US7005560B1 (en) * 1989-10-27 2006-02-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US5959177A (en) * 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US5202422A (en) * 1989-10-27 1993-04-13 The Scripps Research Institute Compositions containing plant-produced glycopolypeptide multimers, multimeric proteins and method of their use
CN1057785A (zh) 1990-04-16 1992-01-15 哈佛大学校长及研究员协会 合成多聚免疫球蛋白受体，受体-抗体复合物，生产及应用
ES2134762T3 (es) 1990-07-20 1999-10-16 Bayer Ag Formas multimericas de proteinas receptoras de rinovirus humanos.
JPH04169539A (ja) 1990-11-01 1992-06-17 Imuno Japan:Kk 消化器疾患治療・予防剤およびその製造方法
EP0664710A4 (de) * 1992-08-07 1998-09-30 Progenics Pharm Inc IMMUNOKONJUGATE BESTEHEND AUS EINEM NICHT-PEPTIDYLEN TEIL UND EINEM CD4-GAMMA2- ODER CD4-IgG2 TEIL, UND VERWENDUNGEN DAVON.
EP0656064B1 (de) 1992-08-17 1997-03-05 Genentech, Inc. Bispezifische immunoadhesine
DE69322289T2 (de) 1992-12-29 1999-05-20 Genentech, Inc., South San Francisco, Calif. Behandlung von entzündlichen darmerkrankungen mit interferon-gamma-inhibitoren
WO1996021012A1 (en) * 1994-12-30 1996-07-11 Planet Biotechnology, Inc. Methods for producing immunoglobulins containing protection proteins in plants and their use
US6046037A (en) * 1994-12-30 2000-04-04 Hiatt; Andrew C. Method for producing immunoglobulins containing protection proteins in plants and their use
US6808709B1 (en) * 1994-12-30 2004-10-26 The Regents Of The University Of California Immunoglobulins containing protection proteins and their use
WO1999049024A2 (en) 1998-03-25 1999-09-30 Planet Biotechnology, Inc. Methods and compositions for production of multimeric proteins in transgenic plants
TR200504220T2 (tr) 1998-12-17 2007-04-24 Biogen Idec Ma Inc. Aktif limfotoksin-beta reseptör imunoglobülin şimeAktif limfotoksin-beta reseptör imunoglobülin şimerik proteinlerinin yüksek düzey ifadesi ve saflaştrik proteinlerinin yüksek düzey ifadesi ve saflaştırılması için bir yöntem.ırılması için bir yöntem.
AU2001245358A1 (en) 2000-02-29 2001-09-12 Auburn University Production of antibodies in transgenic plastids
ATE442386T1 (de) 2000-04-28 2009-09-15 Planet Biotechnology Inc Immunoadhesin zur impfung gegen rhinovirus
US20060015969A1 (en) * 2000-04-28 2006-01-19 Planet Biotechnology, Inc. Novel immunoadhesins for treating and prventing toxicity and pathogen-mediated diseases
US20020168367A1 (en) * 2000-04-28 2002-11-14 Planet Biotechnology Incorporated Novel immunoadhesins for treating and preventing viral and bacterial diseases
WO2002046228A2 (en) 2000-12-05 2002-06-13 Wisconsin Alumni Research Foundation Receptor for b. anthracis toxin
US20070118934A1 (en) * 2001-10-26 2007-05-24 Planet Biotechnology, Inc. Chimeric toxin receptor proteins and chimeric toxin receptor proteins for treatment and prevention of anthrax
GB0423974D0 (en) 2004-10-28 2004-12-01 Ares Trading Sa Proteins

Also Published As

Publication number Publication date
WO2001083529A3 (en) 2002-09-12
JP2003531633A (ja) 2003-10-28
WO2001083529A2 (en) 2001-11-08
CN1440423A (zh) 2003-09-03
EP1290027B1 (de) 2009-09-09
US20080219999A1 (en) 2008-09-11
ES2332872T3 (es) 2010-02-15
CN101643512A (zh) 2010-02-10
AU5744501A (en) 2001-11-12
EP1290027A2 (de) 2003-03-12
US7951378B2 (en) 2011-05-31
JP5008811B2 (ja) 2012-08-22
CA2407426A1 (en) 2001-11-08
AU2001257445B2 (en) 2006-11-02
DK1290027T3 (da) 2010-01-18
DE60139864D1 (de) 2009-10-22

Similar Documents

Publication Publication Date Title
DE60139864D1 (de) Immunoadhesin zur impfung gegen rhinovirus
BRPI0808291A2 (pt) anticorpos anti-ige/ m1, peptideo, composições, ácido nucléico isolado, vetor, célula hospedeira, processo para a produção de um anticorpo anti-ige/m1' apoptótico ou o fragmento funcional, artigo de fabricação, método para depletar espcificamente as células b produtoras de ige, métodos para o tratamento de um doença mediada por ige, para evitar a produção de ige induzida por alérgeno, para reduzir a produção de lge induzida por alérgeno, hibridoma murino, anticorpo e animal transgênico
DE60323340D1 (de) Verfahren zur herstellung interferierender rna-moleküle in säugetierzellen und therapeutische anwendungen solcher moleküle
ATE494358T1 (de) Vorrichtung und verfahren zur fermentation in hohen zelldichten
DE602004002275D1 (de) Verfahren zur herstellung rekombinanterpolyklonaler proteine
SG10201803982TA (en) Antibodies and processes for preparing the same
DE60313188D1 (de) Verfahren und medien zur kontrolle der sialysierung von proteinen, die von säugetierzellen produziert werden
WO2002098210A3 (en) Chromosome doubling method
DE60037896D1 (de) Menschliche antikörper gegen her2/neu
DK0807173T3 (da) Fremgangsmåder til fremstilling af immunoglobuliner indeholdende beskyttelsesproteiner i planter og anvendelse deraf
EA200400345A1 (ru) Человеческие моноклональные антитела к интерлейкину 15 (ил-15), способ их получения и их использование, гибридома, трансфектома, экспрессионный вектор (варианты)
DE60228460D1 (de) Verfahren zur Herstellung und Reinigung von Erythropoietin
WO2005000901A3 (en) Cd20-specific antibodies and methods of employing same
FR2804971B1 (fr) Adn codant une acetohydroxyacide synthase, bacterie le contenant et procede de production de l-valine par culture de cette bacterie
CY1112902T1 (el) Συστημα καλλιεργειας και αναπαραγωγης μικροοργανισμων (για παραδειγμα αλγη) μεσω εντασης φωτος
WO2008024769A3 (en) Intensified perfusion production method
FR2736930B1 (fr) Procede de production, par des cellules vegetales, de proteines heminiques, proteines ainsi obtenues et produits contenant ces proteines
ATE279441T1 (de) Verfahren zur herstellung von genetisch veränderten lymphozyten vorläuferzellen von wirbeltieren und deren gebrauch zur produktion von heterologen bindeproteinen
ATE512230T1 (de) Proteinherstellungsverfahren unter nutzung von yebf
PL367306A1 (pl) Szczepionki na bazie autologicznych komórek T i sposoby ich otrzymywania
DK1714972T3 (da) Fremgangsmåde til fremstilling af et peptid med en pI-værdi over 8 eller under 5
ATE337395T1 (de) Hybridomzelllinie g250 und deren verwendung zur herstellung monoklonaler antikörper
DE60021404D1 (de) System zur herstellung von proteinen
DE60336328D1 (de) Verfahren zur produktion von pflanzen mit verbesserter transpirationseffizienz sowie davon produzierte pflanzen
ATE550934T1 (de) Verfahren zur behandlung von organischen abfällen und vorrichtung zur umsetzung dieses verfahrens

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties
EEWE Authorization for restitution